Aridis' Inhaled Pan-Coronavirus Antibody Cocktail Shows Encouraging Preclinical Action

  • Aridis Pharmaceuticals Inc's ARDS inhaled treatment of its fully human monoclonal antibody cocktail AR-701 resulted in no detectable SARS-CoV-2 virus in the lungs of infected non-human primates.
  • The candidate also protected their lungs from disease. 
  • AR-701 was effective in non-human primates when used either as a prophylactic or therapeutic treatment regimen.
  • Inhaled AR-701 substantially reduced and continued to suppress the viral load in the nasal sinus and oropharynx (upper respiratory tract region) for the entire 5-day testing period.
  • Related Content: Aridis Pharma COVID-19 Antibody Neutralizes Omicron Variant In Animal Study.
  • Additional lab research also indicates that both mAbs in the AR-701 cocktail effectively against the omicron variant and its sub-variants in vitro. 
  • AR-701 is a cocktail of two fully human immunoglobulin G1 mAbs discovered from screening the antibody-secreting B-cells of convalescent COVID-19 patients. 
  • Each mAb of the AR-701 cocktail neutralizes coronaviruses using a distinct mechanism of action: inhibition of viral fusion and entry into human cells (AR-703) or blockage of viral binding to the human 'ACE2' receptor (AR-720). 
  • Price Action: ARDS shares are up 3.64% at $2.28 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!